Literature DB >> 22030071

Is there any place for macrolides in mood disorders?

Rami Bou Khalil1.   

Abstract

Macrolides are protein synthesis inhibitors exerting an action on the bacterial ribosome. The ribosomes coded for by the human mitochondrial deoxyribonucleic acid (DNA) are similar to those from bacteria in size and structure. In addition, mitochondria are thought to have originated from a symbiotic relationship between an anaerobic proto-eukaryotic cell that engulfed an aerobic bacterium. Morphological changes of mitochondria have been observed in bipolar disorder and schizophrenia. Manic episodes associated with the use of antimicrobial agents have been described since the discovery of isoniazid. The oxidative stress induced in the neuronal mitochondria is thought to underlie this effect. The inhibition of GSK-3β in the intra-mitochondrial Akt signaling pathway is thought to convey mood stabilizing properties. Rapamycin is a macrolide that, besides its antiepileptic effect, restores the Akt function and inhibits the mTOR pathway which may have an antidepressant effect. Accordingly, it is hypothesized that rapamycin may have mood stabilizing properties.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030071     DOI: 10.1016/j.mehy.2011.09.046

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

Review 1.  mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders.

Authors:  Larisa Ryskalin; Fiona Limanaqi; Alessandro Frati; Carla L Busceti; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

2.  Individual Copy Number of Ribosomal Genes as a Factor of Mental Retardation and Autism Risk and Severity.

Authors:  Lev Porokhovnik
Journal:  Cells       Date:  2019-09-26       Impact factor: 6.600

3.  A bipolar disorder patient becoming asymptomatic after adjunctive anti-filiarasis treatment: a case report.

Authors:  Nora Hamdani; Raphaël Doukhan; Aline Picard; Ryad Tamouza; Marion Leboyer
Journal:  BMC Psychiatry       Date:  2013-03-13       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.